Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Interim analysis of a non-interventional prospective descriptive study to assess the impact on Patient´s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in routine clinical practice in Spain

Raul Cordoba, María Dolores García, Ruben Fernández, Lucrecia Yanez San Segundo, Raquel Santiago Alonso, Mónica Ballesteros, María José Berruezo, Xabier Gutiérrez, Jose Manuel Puerta, Alicia Rodríguez Fernández, Alexia Suarez Cabrera, Lina María Abenoza, Margarita Fernández, Raul Perez Lopez, Diana Moreno, Jon Badiola, Javier de la Serna

Blood (2025) 146 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2025-2712

Published: 2025

Journal Articles

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Blood (2025) 146 (Supplement 1): 5350.

https://doi.org/10.1182/blood-2025-5350

Published: 2025

Journal Articles

Real-Life Multicenter Experience of the Use of Avatrombopag

Mónica Fernández Pérez, Xabier Gutiérrez López de Ocariz, Carlos Pisón Herrero, Angel Pereda Vicandi, Miren Gabilondo Jalon, Jose María Guinea de Castro, Maria José Ojinaga Begoña, Ana Moreto Quintana, Juan Carlos García-Ruiz, Edwin Uriel Suarez Merchan, Cristina Sierra-Aisa

Blood (2023) 142 (Supplement 1): 5433.

https://doi.org/10.1182/blood-2023-182693

Published: 2023

Journal Articles

Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia

Rosa Ayala, MD PhD, Pau Montesinos, MD PhD, Eva Barragán, PhD, Joaquin Martinez-Lopez, MD, Miguel A. Sanz, Yanira Ruiz-Heredia, Santiago Barrio, Juan Manuel de la Rosa, Inmaculada Rapado, Pilar Martinez, MD, Rafael Colmenares, Maria Pozas, Xabier Gutierrez, María Luz Morales, Noemí Álvarez Sánchez-Redondo

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137467

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Interim analysis of a non-interventional prospective descriptive study to assess the impact on Patient´s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in routine clinical practice in Spain

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Real-Life Multicenter Experience of the Use of Avatrombopag

Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Interim analysis of a non-interventional prospective descriptive study to assess the impact on Patient´s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in routine clinical practice in Spain

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Real-Life Multicenter Experience of the Use of Avatrombopag

Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only